Silencing PSMA2 protein (Proteasome subunit alpha type-2) through AAV-mediated shRNA delivery slowed the progression of breast cancer tumors. This study, developed in collaboration by scientists from iBET and IPATIMUP represents an important milestone for the development of new onco-therapies based in AAV vectors.
Authors and Affiliations: